Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

dendritic cell-gp100-MART-1 antigen vaccine

An autologous dendritic cell vaccine with antineoplastic property. Dendritic cells harvested from cancer patients are pulsed with human gp100 melanoma antigen and MART-1 antigen (a melanoma antigen recognized by T-cells); both antigens are up-regulated in melanomas. Vaccination with this vaccine may elicit the host immune response against MART-1 or gp100 expressing cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:gp100/Mart-1-transduced dendritic cell vaccine
Abbreviation:DC-gp100-MART-1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search